Business Description
MediWound Ltd
NAICS : 325412
SIC : 2834
ISIN : IL0011316309
Description
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.54 | |||||
| Equity-to-Asset | 0.48 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -1.32 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.23 | |||||
| Beneish M-Score | -1.75 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -28.2 | |||||
| 3-Year EBITDA Growth Rate | 34.5 | |||||
| 3-Year EPS without NRI Growth Rate | 15.9 | |||||
| 3-Year FCF Growth Rate | 2.3 | |||||
| 3-Year Book Growth Rate | 22.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 4.69 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.65 | |||||
| 9-Day RSI | 65.65 | |||||
| 14-Day RSI | 63.62 | |||||
| 6-1 Month Momentum % | 92.08 | |||||
| 12-1 Month Momentum % | 26.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.59 | |||||
| Quick Ratio | 4.33 | |||||
| Cash Ratio | 3.84 | |||||
| Days Inventory | 68.2 | |||||
| Days Sales Outstanding | 91.58 | |||||
| Days Payable | 105.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -33.3 | |||||
| Shareholder Yield % | -15.75 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 19.15 | |||||
| Operating Margin % | -82.96 | |||||
| Net Margin % | -35.94 | |||||
| FCF Margin % | -90.6 | |||||
| ROE % | -23.35 | |||||
| ROA % | -10.61 | |||||
| ROIC % | -142.46 | |||||
| ROC (Joel Greenblatt) % | -70.45 | |||||
| ROCE % | -11.4 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.7 | |||||
| PB Ratio | 5.08 | |||||
| Price-to-Tangible-Book | 5.1 | |||||
| EV-to-EBIT | -22.66 | |||||
| EV-to-Forward-EBIT | -7.21 | |||||
| EV-to-EBITDA | -28.81 | |||||
| EV-to-Revenue | 7.4 | |||||
| EV-to-Forward-Revenue | 5.76 | |||||
| EV-to-FCF | -8.17 | |||||
| Price-to-Median-PS-Value | 0.22 | |||||
| Price-to-Net-Current-Asset-Value | 10.8 | |||||
| Price-to-Net-Cash | 24.16 | |||||
| Earnings Yield (Greenblatt) % | -4.41 | |||||
| FCF Yield % | -10.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MDWD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MediWound Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 18.686 | ||
| EPS (TTM) ($) | -0.77 | ||
| Beta | 0.23 | ||
| Volatility % | 63.6 | ||
| 14-Day RSI | 63.62 | ||
| 14-Day ATR ($) | 1.080913 | ||
| 20-Day SMA ($) | 15.579 | ||
| 12-1 Month Momentum % | 26.48 | ||
| 52-Week Range ($) | 7.1 - 18.75 | ||
| Shares Outstanding (Mil) | 9.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MediWound Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MediWound Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
MediWound Ltd Frequently Asked Questions
What is MediWound Ltd(MDWD)'s stock price today?
The current price of MDWD is $17.40. The 52 week high of MDWD is $18.75 and 52 week low is $7.10.
When is next earnings date of MediWound Ltd(MDWD)?
The next earnings date of MediWound Ltd(MDWD) is 2024-05-30 Est..
Does MediWound Ltd(MDWD) pay dividends? If so, how much?
MediWound Ltd(MDWD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers